首席网期刊频道
您所在位置： 首页 > 期刊 > 过刊浏览 > 内科学> 《糖尿病学杂志》> 2003年2月52卷2期>文章精华> 文章详情

NOD Congenic Mice Genetically Protected From Autoimmune Diabetes Remain Resistant to Transplantation Tolerance Induction

首席医学网      2004年11月01日 09:19:56 Monday  
 

作者：Todd Pearson Thomas G. Markees Linda S. WickerDavid V. Serreze Laurence B. Peterson John P. Mordes Aldo A. Rossini and Dale L. Greiner

  加入收藏夹

【关键词】  ,Mice,

1 Program in Immunology and Virology, the University of Massachusetts Medical School, Worcester, Massachusetts
2 Department of Medicine, the University of Massachusetts Medical School, Worcester, Massachusetts
3 Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, University of Cambridge, Cambridge, U.K
4 The Jackson Laboratory, Bar Harbor, Maine
5 Department of Pharmacology, Merck Research Laboratories, Rahway, New Jersey
6 Department of Molecular Medicine, the University of Massachusetts Medical School, Worcester, Massachusetts


　    ABSTRACT
TOP
ABSTRACT
RESEARCH DESIGN AND METHODS
RESULTS
DISCUSSION
REFERENCES
 
The loss of self-tolerance leading to autoimmune type 1 diabetes in the NOD mouse model involves at least 19 genetic loci. In addition to their genetic defects in self-tolerance, NOD mice resist peripheral transplantation tolerance induced by costimulation blockade using donor-specific transfusion and anti-CD154 antibody. Hypothesizing that these two abnormalities might be related, we investigated whether they could be uncoupled through a genetic approach. Diabetes-resistant NOD and C57BL/6 stocks congenic for various reciprocally introduced Idd loci were assessed for their ability to be tolerized. Surprisingly, in NOD congenic mice that are almost completely protected from diabetes, costimulation blockade failed to prolong skin allograft survival. In reciprocal C57BL/6 congenic mice with NOD-derived Idd loci, skin allograft survival was readily prolonged by costimulation blockade. These data indicate that single or multiple combinations of evaluated Idd loci that dramatically reduce diabetes frequency do not correct resistance to peripheral transplantation tolerance induced by costimulation blockade. We suggest that mechanisms controlling autoimmunity and transplantation tolerance in NOD mice are not completely overlapping and are potentially distinct, or that the genetic threshold for normalizing the transplantation tolerance defect is higher than that for preventing autoimmune diabetes.

The nonobese diabetic (NOD) mouse is widely used to model human type 1 diabetes (1). Disease in NOD mice is characterized by T-celldependent autoimmune destruction of ß-cells (2). NOD mice exhibit a number of immune defects that may contribute to their expression of autoimmunity. These include defective macrophage maturation and function (3), low levels of natural killer (NK) cell activity (4), defects in NKT-cells (5,6), deficiencies in their regulatory CD4+CD25+ T-cell population (7), and the absence of C5a and hemolytic complement (8). Additionally, NOD mice are prone to development of other autoimmune syndromes, including autoimmune sialadenitis (9), autoimmune thyroiditis (10), experimental autoimmune encephalomyelitis (11), autoimmune peripheral polyneuropathy (12), and a systemic lupus erythematosus-like disease if exposed to killed mycobacterium (13).

Like humans, susceptibility to type 1 diabetes in the NOD mouse is a polygenic trait, involving at least 19 different Idd loci on 11 chromosomes (14,15). When these NOD genetic susceptibility intervals, either alone or in combination, are replaced by congenic introgression with the corresponding interval from a diabetes-resistant strain, the individual contribution of these Idd loci to potential autoimmune phenotypes can be determined. In many cases, congenic introgression of one or a few Idd loci from resistant strains onto the susceptible NOD strain greatly reduces the incidence of insulitis and diabetes (1620).

We have previously shown that treatment of normal mice with a single donor-specific transfusion (DST) plus a brief course of anti-CD154 (CD40L) monoclonal antibody (mAb) leads to permanent islet (21) and prolonged skin (22) allograft survival. However, transplantation in the NOD mouse presents a unique challenge. Although there are >125 protocols known to prevent diabetes in NOD mice (1), few tolerance-inducing interventions have been reported to be even partially effective in prolonging islet graft survival in diabetic NOD mice (2326). For example, either anti-CD154 mAb monotherapy (27,28) or DST plus anti-CD154 mAb treatment (29), therapies that can induce permanent islet allograft survival in normal mice (30), fail to induce long-term islet graft survival in spontaneously diabetic NOD mice. Because our studies documented that DST and anti-CD154 mAb also failed to prolong the survival of skin allografts, a tissue that is not a target of the autoimmune response, we have hypothesized that NOD mice have a generalized defect in costimulation blockadebased transplantation tolerance induction (29). This defect in tolerance induction was independent of the unique NOD H2g7 haplotype, but it did correlate with a defect in antigen-presenting cell maturation that has previously been described in NOD mice (3,29).

In the present study, we tested the hypothesis that the Idd loci that genetically control diabetes development in NOD mice would also control their resistance to transplantation tolerance. We tested this hypothesis using NOD and C57BL/6 mice with various Idd loci reciprocally introduced by congenic introgression onto each background. To avoid the confounding effects of simultaneously testing both tolerance induction and recurrent autoimmunity to islet-associated antigens, we used skin allografts for our experiments. Our data suggest that the genetic control of peripheral tolerance induction and autoimmunity differ, or are at least only partially overlapping, with the genes that control the induction of costimulation blockadebased peripheral transplantation tolerance.


　    RESEARCH DESIGN AND METHODS
TOP
ABSTRACT
RESEARCH DESIGN AND METHODS
RESULTS
DISCUSSION
REFERENCES
 
Animals.
C57BL/6 (H2b), C3H/HeJ (H2k), and BALB/c (H2d) mice were obtained from the National Cancer Institute (Frederick, MD). NOD/MrkTacfBR, NOD.B6 Idd3R450, NOD.B10 Idd5R444, NOD.B6 Idd3R450 B10 Idd5R8, NOD.B10 Idd9R28, NOD.B6 Idd10Idd18R, and NOD.B6 Idd3Idd10Idd18R323 (all H2g7) were obtained from Taconic Farms (Germantown, NY). NOD/Lt (H2g7) mice were purchased from The Jackson Laboratory (Bar Harbor, ME). C57BL/6.NODc1c, C57BL/6.NODc1t, C57BL/6.NODc3, and C57BL/6.NODc6 mice (H2b; developed by Edward Wakeland, University of Texas Southwestern Medical Center, Dallas, TX) were the gift of Dr. Edward Leiter (The Jackson Laboratory). B10.D2-HC0 (genetic designation: B10.D2-H2d H2-T18c Hc0/oSnJ) and B10D2-HC1 mice (genetic designation: B10.D2-H2d H2-T18c Hc1/nSnJ) were obtained from The Jackson Laboratory.  summarizes the congenic interval(s) and diabetes incidence of each of the congenic mouse strains listed above that were used in these experiments.


fig.ommtted  Idd congenic intervals, cumulative diabetes frequency and insulitis, and candidate genes in each interval

　

 
All animals were certified to be free of Sendai virus, pneumonia virus of mice, murine hepatitis virus, minute virus of mice, ectromelia, lactate dehydrogenaseelevating virus, mouse poliovirus, Reo-3 virus, mouse adenovirus, lymphocytic choriomeningitis virus, polyoma, Mycoplasma pulmonis, and Encephalitozoon cuniculi. They were housed in a specific pathogen-free facility in microisolator cages and given autoclaved food and acidified water ad libitum. All animal use was in accordance with the guidelines of the institutional animal care and use committee of the University of Massachusetts Medical School and recommendations in the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, National Research Council, National Academy of Sciences, 1996).

Tolerance induction and skin allograft transplantation.
Graft recipient mice were treated with DST and anti-CD154 mAb and transplanted with skin allografts as described (22,31). Briefly, the DST consisted of a single intravenous injection of 107 C3H/HeJ or BALB/c female spleen cells obtained from 5- to 10-week-old donors. The DST was injected on day -7 relative to skin transplantation. Clone MR1 hamster anti-mouse CD154 mAb (32) was produced as ascites in scid mice and purified by protein A affinity chromatography (Amersham Pharmacia Biotech, Uppsala, Sweden). Antibody concentration was determined by measurement of optical density and confirmed by enzyme-linked immunosorbent assay (ELISA) as described previously (33). The concentration of contaminating endotoxin was determined commercially (Charles River Endosafe, Charleston, SC) and was uniformly <10 endotoxin units per milligram of mAb. Mice were injected intraperitoneally with anti-CD154 mAb (0.25 or 0.5 mg/dose as indicated in text) on days -7, -4, 0, and +4 relative to skin transplantation. Full-thickness skin grafts 12 cm in diameter were obtained from the flanks of donor mice and transplanted onto the dorsal flanks of recipients as described (22). Grafts were examined three times weekly, and rejection was defined as the first day on which the entire graft surface appeared necrotic (22). Grafts adherent to the bandage or fully necrotic on day 7 were deemed technical failures and were excluded from analysis (22).

Serum levels of hamster anti-CD154 mAb.
Clearance kinetics of the hamster MR1 anti-CD154 mAb was determined in groups of NOD and C57BL/6 mice that were given a single intraperitoneal injection of 2.0 mg of antibody. Serum was collected from blood obtained on days 13, 17, 20, 24, 32, and 40 after antibody injection. MR1 hamster IgG levels were quantified in the serum samples by ELISA (33).

Statistics.
The average duration of graft survival is presented as the median. Graft survival among groups was compared using the method of Kaplan and Meier (34). The equality of allograft survival distributions for animals in different treatment groups was tested using the log rank statistic (34). P values <0.05 were considered statistically significant. Comparisons of two means used unpaired t tests (35). MR1 clearance rates were calculated by single-phase exponential decay curves fitted by regression analysis using Prism (Version 3.0; Graphpad Software, San Diego, CA).


　    RESULTS
TOP
ABSTRACT
RESEARCH DESIGN AND METHODS
RESULTS
DISCUSSION
REFERENCES
 
Costimulation blockade prolongs skin allograft survival in mice genetically deficient in C5a and hemolytic complement.
The NOD mouse has numerous immune defects that may be involved in their resistance to the induction of transplantation tolerance. One defect that could impact this strain’s response to in vivo antibody therapy is the absence of hemolytic complement caused by their genetic deficiency in C5a (8). To test this, we attempted to tolerize B10.D2 congenic mice that genetically differ in the presence or absence of C5a (36). These congenic mice were treated with DST, anti-CD154 mAb, and C3H/HeJ skin allografts. As shown in , the genetic absence of C5a in B10.D2-HC0 mice did not impair prolongation of skin allograft survival induced by costimulation blockade (median survival time [MST] = 54 days), and in fact, it slightly prolonged skin allograft survival as compared with similarly treated B10.D2-HC1 mice in which C5a was present (MST = 39 days, P < 0.01).


fig.ommtted  Skin allograft survival in mice genetically deficient in hemolytic complement. Skin allograft survival was determined in B10.D2 mice (H2d) treated with DST and anti-CD154 mAb that have C5a (HC1) or are genetically deficient in C5a (HC0) and hemolytic complement. Male mice 610 weeks of age were treated with four doses of 0.25 mg anti-CD154 mAb and a single DST and given a C3H/HeJ skin graft, as described in RESEARCH DESIGN AND METHODS. B10.D2 HC0 recipients genetically deficient in C5a had significantly prolonged skin allograft survival as compared with mice with C5a (P < 0.01).

　

 
Clearance kinetics of anti-CD154 mAb are normal in NOD mice.
In a related experiment, we sought to determine whether NOD mice are resistant to tolerance induction because of an accelerated clearance rate of anti-CD154 mAb from the circulation. We have previously documented that skin allograft rejection in tolerized mice is inversely correlated with the level of circulating anti-CD154 mAb (33). Groups of NOD and C57BL/6 mice were given a single intraperitoneal injection of 2.0 mg of anti-CD154 mAb. The concentration of MR1 in their serum was determined periodically between days 13 and 40 after injection to calculate the clearance rate of the antibody. The serum concentration of antibody on day 13 in NOD and C57BL/6 mice was ~300 mcg/ml and declined to 100 mcg/ml in both groups by day 40. The calculated half life of MR1 in NOD (10.7 days, n = 6) and C57BL/6 (10.4 days, n = 5) mice was similar. The serum concentrations at these time points after antibody injection and clearance rates of antibody are comparable to those we observed in CBA mice (33). These data document that neither the absence of hemolytic complement nor an accelerated clearance of anti-CD154 mAb in NOD mice accounts for the inability of costimulation blockade to prolong skin graft survival.

Costimulation blockade prolongs skin allograft survival in C57BL/6 congenic mice with NOD susceptibility loci.
We next tested the hypothesis that selected NOD-derived Idd susceptibility loci are responsible for the defect in peripheral transplantation tolerance induction by costimulation blockade. This was first assessed by determining whether the ability to prolong skin allograft survival was abrogated in C57BL/6 mice congenic for various NOD-derived Idd loci (22). None of the C57BL/6 congenic mice developed insulitis or diabetes . We tested four congenic strains. C57BL/6.NODc1c mice carry the NOD-derived Idd5.1 region, which includes genes encoding CD152 (CTLA4) and CD28, costimulatory molecules that are important for tolerance induction and immune activation (21). C57BL/6.NODc1t mice carry the NOD-derived Idd5.1 as well as the Idd5.2 region, which includes the CXCR2 and interleukin-8 receptor genes. C57BL/6.NODc3 mice carry the NOD-derived Idd3, Idd17, Idd10, and Idd18 loci, which include genes that control cell activation. C57BL/6.NODc6 mice carry the NOD Idd6 locus, which includes genes contained within the NK receptor protein-1a (NKR-P1) complex .

The median skin allograft survival time of each of these C57BL/6 congenic strains ranged from 62 to >93 days and were statistically similar to that observed in C57BL/6 wild-type mice (MST = 81 to >94 days). Skin allograft survival in the C57BL/6 congenic mice was significantly greater than that observed in similarly treated NOD mice (MST = 2024 days) .


fig.ommtted  Skin allograft survival on C57BL/6 mice congenic for the NOD Idd intervals

　

 

fig.ommtted Skin allograft survival on Idd3/Idd5 congenic NOD mice

　

 

fig.ommtted Skin allograft survival on Idd3/Idd10/Idd18 and Idd9 congenic NOD mice

　

 
Diabetes-resistant NOD congenic mice treated with DST and anti-CD154 mAb rapidly reject skin allografts.
We next determined whether NOD stocks congenic for selected C57BL/6- or C57BL/10-derived Idd loci that mediate protection from insulitis and diabetes would also exhibit prolonged skin allograft survival after treatment with DST and anti-CD154 mAb. We tested three groups of NOD congenic mice with intervals that encompass the nonmajor histocompatibility complex (MHC) Idd loci with the greatest effect on diabetes expression (18,3739). The first of these were NOD congenic stocks carrying a C57BL/6-derived Idd3 or C57BL/10-derived Idd5 locus alone or in combination. These NOD single-Idd congenic mice each have a reduced frequency of diabetes, and when the Idd3 and Idd5 resistance loci are combined, the frequency of diabetes is reduced to 1%, and insulitis is absent in most mice (18) . The median survival time of C3H/HeJ skin allografts in these NOD congenic mice treated with DST plus anti-CD154 mAb (2431 days) was statistically significantly shorter than that of C57BL/6 mice (>115 days) . Skin allograft survival in these NOD congenic mice was similar to that of NOD/Lt (MST = 20 days) or NOD/MrkTac (MST = 23 days) mice .

We next tested NOD congenic mice that carried various combinations of C57BL/6-derived Idd3, Idd10, and Idd18 resistance loci. The frequency of diabetes in these NOD congenic mice varies from 9 to 50% . A significant reduction in the frequency of insulitis was also observed in NOD.B6 Idd3/10/18 triple congenic mice (40,41). Again, all of the NOD congenic strains with various combinations of these genetic intervals were resistant to tolerance induction and had median skin allograft survival times of 1729 days .

Finally, we tested an NOD stock congenic for the C57BL/10-derived Idd9 locus. This locus contains molecular variants of Cd30, Tnfr2, and Cd137 (39), and these mice have a frequency of diabetes of only 3% . The MST of skin allografts in NOD.B10 Idd9 mice was 20 days, similar to that observed in NOD/Lt mice (MST = 24 days, ).


　    DISCUSSION
TOP
ABSTRACT
RESEARCH DESIGN AND METHODS
RESULTS
DISCUSSION
REFERENCES
 
In the present study, we have investigated the relationship between genes that control autoimmune diabetes expression in NOD mice with those controlling their resistance to transplantation tolerance induced by costimulation blockade. We document that single or small combinations of the evaluated C57BL/6-derived Idd loci that dramatically alter diabetes expression are not able to correct the response of NOD mice to costimulation blockade and, conversely, that NOD-derived Idd loci do not shorten skin allograft survival in C57BL/6 mice. We further eliminate two other potential explanations: the genetic absence of hemolytic complement or an accelerated clearance rate of anti-CD154 mAb from the circulation.

Peripheral transplantation tolerance induction by DST and anti-CD154 mAb involves the deletion of alloreactive CD8+ T-cells (31,33). Because CD8+ T-cells in NOD mice appear to be resistant to tolerance induction (42), this may be one mechanism by which NOD mice are resistant to costimulation blockadeinduced tolerance. However, we have recently determined that the majority of high-affinity alloreactive CD4+ T-cells are also deleted by treatment with DST and anti-CD154 mAb (D.L.G., unpublished observations). CD4+ T-cells express CD154 when activated (32). This suggests that one mechanism by which DST and anti-CD154 mAb induces tolerance could involve deletion of alloreactive CD4+ T-cells by antibody-mediated, complement-dependent lysis. However, the ability to prolong skin allograft survival in congenic B10.D2 mice that lacked C5a and hemolytic complement argues that this defect does not prevent tolerance induction in NOD mice. We have also documented that the circulating level of anti-CD154 mAb is inversely correlated with skin allograft survival in recipients treated with DST and anti-CD154 mAb (33). However, the clearance rate of anti-CD154 mAb from the circulation of NOD mice was similar to that of C57BL/6 mice. This data suggests that rapid clearance of anti-CD154 mAb, hence potentially lowering anti-CD154 mAb concentrations below effective tolerizing levels (~100 mcg/ml) (33), was not the basis for the resistance of NOD mice to tolerance induction.

We then tested the hypothesis that some of the genetic loci associated with development of autoimmune diabetes in NOD mice would also be important in their resistance to induction of peripheral transplantation tolerance. Prolonged allograft survival was not abrogated in C57BL/6 stocks congenic for any of the analyzed NOD-derived Idd susceptibility loci. We note, however, that no combination of Idd susceptibility loci introgressed into C57BL/6 mice to date has rendered them susceptible to the spontaneous development of insulitis or autoimmune diabetes.

Similarly, none of the analyzed C57BL/6- or C57BL/10-derived Idd congenic intervals that confer various degrees of diabetes resistance to NOD mice restored their ability to be tolerized by DST and anti-CD154 mAb treatment. This observation was surprising because congenic introgression of even a few of the Idd resistance loci into NOD mice profoundly reduces the frequency of insulitis and diabetes (17,18,38,39) . Furthermore, many of the tested Idd congenic intervals are characterized by polymorphisms in genes important for costimulation and immune activation.

There is evidence that autoimmune diabetes in NOD mice is due primarily to defects in central tolerance (43). Bone marrow chimerism is known to prevent autoimmunity in NOD mice by this mechanism (44). In humans, bone marrow cells from diabetic donors have been documented to adoptively transfer disease to nondiabetic recipients, suggesting that central tolerance defects are also important in type 1 diabetes in humans (45). Additionally, there is data to suggest that manipulation of the peripheral immune system can affect self-tolerance and the expression of autoimmune diabetes in NOD mice (4648). Mechanisms that control central and peripheral tolerance are different. Central tolerance is primarily mediated by intrathymic deletion of autoreactive T-cells during thymic development, whereas peripheral tolerance is mediated by multiple mechanisms, including deletion, anergy, and regulatory processes (21).

It is currently unknown whether improved central or peripheral tolerance is the mechanism by which the NOD congenic mice we studied in these experiments were rendered resistant to autoimmune diabetes. Our data suggest, however, that if the mechanism of protection from diabetes is due to restoration of the factors that permit peripheral regulation of autoimmunity, these mechanisms are not sufficient for the induction of peripheral allogeneic transplantation tolerance by costimulation blockade. Alternatively, it is possible that the results from the current study reflect the fact that more Idd resistance loci are required to genetically alter the phenotype of abnormal transplantation tolerance induction in NOD mice than are required to decrease the incidence of spontaneous autoimmune diabetes. Specifically, peripheral transplantation tolerance induction by costimulation blockade may be under the control of a complex combination of Idd loci not yet tested. Future experiments examining C57BL/6.H2g7 congenic mice bearing NOD diabetes-susceptibility loci will be required to identify potential interactions of the unique NOD H2g7 MHC with these genetic loci and their effect on tolerance induction. However, these data raise the possibility that the loss of self-tolerance leading to autoimmunity in NOD mice may be mediated by mechanisms that differ, in part, from their resistance to peripheral transplantation tolerance, a hypothesis we are currently testing.

　


　    ACKNOWLEDGMENTS
 
This study was supported in part by grants AR35506 and AI42669 and an institutional Diabetes Endocrinology Research Center (DERC) grant DK52530 from the National Institutes of Health and by grant DK53006 jointly funded by the National Institutes of Health and the Juvenile Diabetes Research Foundation (JDRF). L.S.W. is supported by a joint grant from the JDRF and the Wellcome Trust. D.V.S. is supported by grants DK46266 and DK51090 from the National Institutes of Health and by a grant from the JDRF. The availability of NOD congenic mice through the Taconic Farms Emerging Models Program has been supported by grants from the Merck Genome Research Institute, National Institute of Allergy and Infectious Diseases (NIAID), and the JDRF.

We thank Linda Paquin, Stephanie Gibbons, Linda Leehy, and Jean Leif for technical assistance.


　    REFERENCES
TOP
ABSTRACT
RESEARCH DESIGN AND METHODS
RESULTS
DISCUSSION
REFERENCES
 
  1. Atkinson M, Leiter EH: The NOD mouse model of insulin dependent diabetes: As good as it gets? Nature Med5 :601 604,1999
  2. Leiter EH: NOD mice and related strains: origins, husbandry, and biology. In NOD Mice and Related Strains: Research Applications in Diabetes AIDS, Cancer and Other Diseases. Leiter EH, Atkinson MA, Eds. Austin, TX, R.G. Landes,1998 , p.1 36
  3. Serreze DV, Gaedeke JW, Leiter EH: Hematopoietic stem-cell defects underlying abnormal macrophage development and maturation in NOD/Lt mice: defective regulation of cytokine receptors and protein kinase C. Proc Natl Acad Sci U S A90 :9625 9629,1993
  4. Kataoka S, Satoh J, Fujiya H, Toyota T, Suzuki R, Itoh K, Kumagai K: Immunologic aspects of the nonobese diabetic (NOD) mouse: abnormalities of cellular immunity. Diabetes32 :247 253,1983
  5. Naumov YN, Bahjat KS, Gausling R, Abraham R, Exley MA, Koezuka Y, Balk SB, Strominger JL, Clare-Salzler M, Wilson SB: Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets. Proc Natl Acad Sci U S A98 :13838 13843,2001
  6. Wang B, Geng YB, Wang CR: CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes. J Exp Med194 :313 319,2001
  7. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA: B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity12 :431 440,2000
  8. Baxter AG, Cooke A: Complement lytic activity has no role in the pathogenesis of autoimmune diabetes in NOD mice. Diabetes42 :1574 1578,1993
  9. Hu Y, Nakagawa Y, Purushotham KR, Humphreys-Beher MG: Functional changes in salivary glands of autoimmune disease-prone NOD mice. Am J Physiol Endocrinol Metab263 :E607 E614,1992
  10. Many MC, Maniratunga S, Denef JF: The non-obese diabetic (NOD) mouse: an animal model for autoimmune thyroiditis. Exp Clin Endocrinol Diabetes104 (Suppl. 3) :17 20,1996
  11. Girvin AR, Dal Canto PC, Rhee L, Salomon B, Sharpe A, Bluestone JA, Miller SD: A critical role for B7/CD28 costimulation in experimental autoimmune encephalomyelitis: a comparative study using costimulatory molecule-deficient mice and monoclonal antibody blockade. J Immunol164 :136 143,2000
  12. Salomon B, Rhee L, Bour-Jordan H, Hsin H, Montag A, Soliven B, Arcella J, Girvin AM, Miller SD, Bluestone JA: Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice. J Exp Med194 :677 684,2001
  13. Silveira PA, Baxter AG: The NOD mouse as a model of SLE. Autoimmunity34 :53 64,2001
  14. Wicker LS, Todd JA, Peterson LB: Genetic control of autoimmune diabetes in the NOD mouse. Annu Rev Immunol13 :179 200,1995
  15. Serreze DV, Leiter EH: Genetic and pathogenic basis of autoimmune diabetes in NOD mice. Curr Opinion Immunol6 :900 906,1994
  16. Serreze DV, Bridgett M, Chapman HD, Chen E, Richard SD, Leiter EH: Subcongenic analysis of the Idd13 locus in NOD/Lt mice: evidence for several susceptibility genes including a possible diabetogenic role for beta2-microglobulin. J Immunol160 :1472 1478,1998
  17. Lyons PA, Armitage N, Lord CJ, Phillips MS, Todd JA, Peterson LB, Wicker LS: Mapping by genetic interaction: high-resolution congenic mapping of the type 1 diabetes loci Idd10 and Idd18 in the NOD mouse. Diabetes50 :2633 2637,2001
  18. Hill NJ, Lyons PA, Armitage N, Todd JA, Wicker LS, Peterson LB: NOD Idd5 locus controls insulitis and diabetes and overlaps the orthologous CTLA4/IDDM12 and NRAMP1 loci in humans. Diabetes49 :1744 1747,2000
  19. Lamhamedi-Cherradi SE, Boulard O, Gonzalez C, Kassis N, Damotte D, Eloy L, Fluteau G, Lévi-Strauss M, Garchon HJ: Further mapping of the Idd5.1 locus for autoimmune diabetes in NOD mice. Diabetes50 :2874 2878,2001
  20. Caillat-Zucman S, Bach JF: Genetic predisposition to IDDM. Clin Rev Allergy Immunol19 :227 246,2000
  21. Rossini AA, Greiner DL, Mordes JP: Induction of immunological tolerance for transplantation. Physiol Rev79 :99 141,1999
  22. Markees TG, Phillips NE, Gordon EJ, Noelle RJ, Shultz LD, Mordes JP, Greiner DL, Rossini AA: Long-term survival of skin allografts induced b

  订阅登记：

请您在下面输入常用的Email地址、职业以便我们定期通过邮箱发送给您最新的相关医学信息，感谢您浏览首席医学网！

邮箱：    职业：